Clinical Trial Update: Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety and efficacy of durvalumab in combination with neoadjuvant chemotherapy for localized Luminal B HER2-negative and triple-negat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Luminal Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Grand Hôpital de Charleroi | Conditions: Breast Cancer, Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED